Technical Reference

Model Formulas, Parameters, and Code Documentation

🔬 Workshop: Cultured Meat Cost Trajectories (Late April / Early May 2026)

This model feeds into The Unjournal’s upcoming expert workshop on CM production costs. Workshop details & signup →

💬 We Want Your Feedback!

Comment directly on this page using Hypothesis — click the < tab on the right edge. Highlight any equation, parameter, or explanation to annotate it. We actively monitor comments and will respond to questions, incorporate suggestions, and improve the documentation based on your feedback.

Tip

Return to: Interactive Cost Model | New to this topic? How Cultured Chicken is Made | 🎧 Audio Review (22 min MP3)

Overview

This document provides complete technical documentation for the cultured chicken cost model:

Model Formulas

This section presents the model structure top-down: starting with the final output and unpacking each component.

# Component Equation Key variables
1 Total Cost Unit Cost = VOC + CAPEX/kg + Fixed/kg + Downstream/kg —
2 VOC VOC = Media + Micros + GFs + Other —
2a Media (1000/density) × turnover × $/L density (g/L), turnover, \(/L | | 2b | **[Growth Factors](#growth-factor-cost)** | g_GF × P_GF | quantity (g/kg), price (\)/g)
3 CAPEX/kg (CAPEX × CRF) / Output CRF, annual output
3a CRF r(1+r)^n / ((1+r)^n - 1) r=WACC, n=years
3b Scale CAPEX_ref × (Q/Q_ref)^s s=0.6-0.9
4 Adoption bound(P_base + k(m-0.5), 0, 1) k, m (maturity)

Click any link to jump to the detailed explanation.

1. Total Unit Cost

The model estimates unit production cost ($/kg) by summing four components:

\[\boxed{\text{Unit Cost} = \underbrace{\text{VOC}}_{\text{variable}} + \underbrace{\text{CAPEX}_{/\text{kg}}}_{\text{capital}} + \underbrace{\text{Fixed OPEX}_{/\text{kg}}}_{\text{overhead}} + \underbrace{\text{Downstream}_{/\text{kg}}}_{\text{optional}}}\]

What does each term mean?
Term Description Typical range
VOC Variable operating costs — inputs that scale with production $5–100/kg
CAPEX/kg Annualized capital costs (bioreactors, facilities) $1–20/kg
Fixed OPEX/kg Labor, maintenance, overhead $1–10/kg
Downstream/kg Scaffolding, texturization (for structured products) $2–15/kg if enabled

2. Variable Operating Costs (VOC)

VOC is the sum of four input categories:

\[\text{VOC} = \text{Media} + \text{Micronutrients} + \text{Growth Factors} + \text{Other}\]

2a. Media Cost

Media is the liquid nutrient broth that feeds growing cells. Media cost depends on how much liquid you need per kg of meat:

\[\text{Media Cost} = \underbrace{\left(\frac{1000}{\text{density}}\right)}_{\text{L per kg wet cells}} \times \underbrace{\text{turnover}}_{\text{media changes}} \times \underbrace{\text{price}}_{\text{\$/L}}\]

Variable definitions:

  • Cell density (g/L): Final concentration of cells at harvest. Higher density = less media needed per kg. The 1000 converts g/L to L/kg (since 1 kg = 1000 g).
  • Media turnover: How many times the media volume is replaced during a production run. Batch systems (turnover = 1) use one fill; perfusion systems (turnover = 3–10) continuously flow fresh media through.
  • Price ($/L): Cost per liter of complete media formulation.

Example calculation:

  • Cell density: 50 g/L → need 1000/50 = 20 L per kg
  • Media turnover: 3× (perfusion system) → 20 × 3 = 60 L total per kg
  • Media price: $0.50/L (hydrolysates) → 60 × 0.50 = $30/kg

Why does density vary? Achievable density depends on cell type, bioreactor design, and operating mode. Batch cultures typically reach 30–50 g/L; perfusion cultures with optimized conditions can reach 100–200 g/L (Humbird 2021).

Hydrolysates vs. pharma-grade amino acids:

Scenario Price range ($/L) What it means Source
With hydrolysates $0.20 – $1.20 Amino acids from digested plant/yeast proteins O’Neill et al. 2021, Believer 2024
Pharma-grade amino acids $1.00 – $4.00 Individual purified amino acids Humbird 2021

Hydrolysates cost less because they’re produced from commodity feedstocks via enzymatic digestion, rather than synthetic chemistry or purification.

Is $/L meaningful if density varies?

Yes. Media cost ($/L) refers to the cost of preparing one liter of complete growth medium — the liquid that fills the bioreactor. This cost is relatively fixed for a given formulation, regardless of how many cells you eventually grow in it.

What varies is $/kg meat, which depends on:

  • How dense the cells grow (cell density, g/L)
  • How many times you replace the media (turnover)

A $1/L medium costs $60/kg meat at 50 g/L density × 3 turnover, but only $15/kg meat at 200 g/L × 1 turnover. The $/L is the input; $/kg is the output.

Media Cost per kg at Different Cell Densities

Since both $/L and cell density matter, here’s how they combine (assuming turnover = 3):

Cell density Liters/kg @ $0.50/L (hydrolysates) @ $2.00/L (pharma-grade)
30 g/L 100 L $50/kg $200/kg
50 g/L 60 L $30/kg $120/kg
100 g/L 30 L $15/kg $60/kg
200 g/L 15 L $7.50/kg $30/kg

Key insight: Doubling cell density cuts media cost in half — density improvements are as valuable as halving media price.

2b. Growth Factor Cost

Growth factors are signaling proteins that tell cells to proliferate. They are the most price-volatile component.

Key growth factors used in cultured meat:

Abbreviation Full name Function Why it’s needed
FGF-2 Fibroblast Growth Factor 2 Promotes cell proliferation Keeps cells dividing; prevents differentiation
IGF-1 Insulin-like Growth Factor 1 Cell growth and survival Supports metabolism and prevents cell death
TGF-β Transforming Growth Factor β Differentiation control Triggers muscle fiber formation at end of culture

Growth factor cost equation:

\[\text{GF Cost} = \underbrace{g_{\text{GF}}}_{\text{grams/kg meat}} \times \underbrace{P_{\text{GF}}}_{\text{\$/gram}}\]

How GF Cost Feeds into Total Cost

Growth factor cost is one of the four components of Variable Operating Costs:

\[\text{VOC} = \text{Media} + \text{Micronutrients} + \underbrace{\text{Growth Factors}}_{\text{this section}} + \text{Other}\]

And VOC feeds into total unit cost (see Section 1).

Two Ways to Explore GF Uncertainty

The dashboard provides two controls for growth factor prices that work together:

Control What it does When to use
Binary toggle (Bernoulli) Flips between “cheap” and “expensive” price regimes Default Monte Carlo — samples from uncertain future
Progress slider Manually sets a point between current and target prices Scenario analysis — “what if we’re 50% of the way there?”

How they interact: The slider overrides the binary toggle. When you move the slider from 0%, you’re saying “ignore the coin flip; assume this level of progress.”

The Progress Slider Formula

The slider interpolates between current prices (0%) and target prices (100%):

\[P_{\text{GF}} = P_{\text{current}} \times (0.01)^{\text{progress}}\]

In plain text: GF Price = Current Price x (0.01)^progress, where the exponent “progress” ranges from 0 (no progress) to 1 (full breakthrough).

How to read this formula:

  • \(P_{\text{current}}\) = today’s growth factor prices (the starting point)
  • \(\text{progress}\) = a value from 0 to 1 (the slider position, where 0 = 0% and 1 = 100%)
  • \((0.01)^{\text{progress}}\) = the price multiplier, which shrinks as progress increases

Why the base 0.01? We chose 0.01 because industry targets are roughly 100× cheaper than current prices. Since \(0.01^1 = 0.01 = 1/100\), setting progress to 100% gives a 100× price reduction — matching GFI’s target estimates:

  • Current FGF-2: ~$50,000/g → Target: ~$500/g (100× reduction)
  • Current TGF-β: ~$1,000,000/g → Target: ~$10,000/g (100× reduction)
Progress slider Price multiplier Intuition
0% × 1.00 Today’s prices
25% × 0.32 ~3× cheaper
50% × 0.10 ~10× cheaper
75% × 0.032 ~30× cheaper
100% × 0.01 ~100× cheaper (targets achieved)

The Binary “Cheap vs. Expensive” Toggle

In Monte Carlo mode (slider at 0%), the model flips a coin (50% probability by default) to select between two price regimes:

“Expensive” regime (limited progress):

Parameter Range Source
Quantity 0.0005 – 0.02 g/kg Higher usage due to degradation
Price $500 – $50,000/g Current FGF-2 ~$50,000/g, TGF-β up to $1M/g (GFI analysis)

“Cheap” regime (breakthrough achieved):

Parameter Range Source
Quantity 0.0001 – 0.005 g/kg Lower usage (thermostable, recycling)
Price $1 – $100/g GFI industry targets — studies suggest $4/g achievable

Why binary, not continuous? The breakthrough technologies are substitutes:

  • Autocrine cell lines — cells produce their own FGF2 → GF cost ≈ $0
  • Plant molecular farming — target $1-10/g
  • Precision fermentation — target $10-100/g

If any one succeeds, the industry shifts to the cheap regime. We’re asking “will at least one breakthrough work?” — a yes/no question.

Why not model each technology separately?

The objection: “Each breakthrough technology has independent effects on GF cost. Why collapse them into a single binary switch?”

Our reasoning:

  1. Substitutes, not complements: You only need one cheap GF source. If autocrine lines work, you don’t also need plant farming. Multiple successes don’t stack — the first success captures most of the value.

  2. Correlated outcomes: The technologies share underlying capabilities (protein engineering, regulatory approval for novel food ingredients, scale-up expertise). If one succeeds, others are more likely to succeed too. Treating them as independent would understate the probability of at least one working.

  3. Parsimony: Modeling 4+ independent technologies with separate probabilities, partial success states, and interactions would add many parameters without clear empirical grounding. The binary approach captures the key decision-relevant question: “Will GF costs be a dealbreaker or not?”

What we lose: The binary model can’t represent “partial success” scenarios where, say, precision fermentation reaches $50/g (10× improvement but not full breakthrough). The progress slider partially addresses this for scenario analysis.

Alternative approach (not implemented): A continuous model could sample GF price from a mixture distribution — e.g., 50% chance of $1-100/g, 50% chance of $500-50,000/g. This would be mathematically equivalent but less interpretable.

3. Annualized Capital Costs

Capital costs are annualized using the Capital Recovery Factor (CRF):

\[\text{CAPEX}_{/\text{kg}} = \frac{\text{Total CAPEX} \times \text{CRF}}{\text{Annual Output (kg)}}\]

Where CRF converts a lump sum to annual payments:

\[\text{CRF} = \frac{r \cdot (1+r)^n}{(1+r)^n - 1}\]

Variables in this formula:

  • \(r\) = WACC (weighted average cost of capital) — your cost of financing
  • \(n\) = asset life in years — how long the equipment lasts
What is CRF? (Intuitive explanation)

Capital Recovery Factor answers: “If I borrow $X at interest rate \(r\) for \(n\) years, what annual payment covers both principal and interest?”

Intuition: Think of CRF as the “annual rent” you pay on capital. If you buy a $100M facility:

  • At CRF = 10%, you pay $10M/year
  • At CRF = 20%, you pay $20M/year

CRF is always higher than just “1/asset_life” because you’re also paying interest, not just depreciation.

Why does the formula look so complicated?

The formula \(\text{CRF} = \frac{r(1+r)^n}{(1+r)^n - 1}\) comes from the math of constant payments over time. Here’s the intuition:

  1. If you borrowed $100 at 10% interest for 1 year, you’d owe $110 at the end → CRF = 110% (or 1.10)
  2. If you could pay over 2 years with equal payments, each payment is smaller, but you pay more total interest → CRF ≈ 58%
  3. As the loan period gets longer, each payment shrinks, but the total interest paid grows
  4. The formula balances these two effects to give you the constant annual payment

Numerical example: At r=10%, n=15 years: - CRF = 0.10 × (1.10)^15 / ((1.10)^15 - 1) = 0.10 × 4.18 / 3.18 = 13.1% - A $100M facility costs $13.1M/year to finance

Why does CRF matter? It converts a one-time construction cost into an annual charge that gets divided across all kg produced. Higher CRF = higher $/kg.

WACC (\(r\)) Asset Life (\(n\)) CRF Annual payment on $100M Source context
10% 15 years 13.1% $13.1M/year Established food company financing
15% 10 years 19.9% $19.9M/year Growth-stage company
20% 8 years 26.1% $26.1M/year Early-stage / high-risk (Humbird 2021)

Higher WACC or shorter asset life → higher annual capital charge → higher $/kg.

4. Technology Adoption & Maturity

The model uses a maturity factor to create realistic correlations between different aspects of industry development. Without this, the Monte Carlo simulation would generate unrealistic scenarios (e.g., breakthrough growth factor technology but prohibitively expensive financing).

Why should these be correlated? The underlying logic is not that technology causes cheaper financing or vice versa. Rather, both are driven by a common set of enabling conditions – investor confidence, regulatory clarity, talent availability, and demonstrated unit economics. In a world where the cultured meat industry develops well by the projection year, we would expect both technological breakthroughs and improved financing terms, because both flow from the same underlying industry momentum. See the detailed explanation below for the full causal story.

The Maturity Factor (\(m\))

The maturity factor is a single number between 0 and 1 representing overall industry development:

  • \(m = 0\): Nascent industry — early R&D stage, no scale-up
  • \(m = 0.5\): Moderate development — pilots running, some commercial activity
  • \(m = 1\): Mature industry — established supply chains, proven technology

Each simulation draws \(m\) from a Beta distribution (default: mean 0.5, stdev 0.2).

How Maturity Adjusts Adoption Probabilities

Each technology’s adoption probability is adjusted based on the maturity draw. The key variables are \(k\) (sensitivity coefficient – how strongly maturity affects this technology) and \(m\) (the maturity factor – overall industry development level):

\[P_{\text{adopted}} = \text{bound}\Big(P_{\text{base}} + k \cdot (m - 0.5),\; 0,\; 1\Big)\]

Variable definitions (all terms in the equation above):

Variable Meaning Typical values
\(P_{\text{base}}\) Base adoption probability set by the user via slider 0.50–0.75
\(k\) Sensitivity coefficient — how strongly maturity affects this technology’s adoption 0.20–0.30
\(m\) Maturity factor — overall industry development level, drawn from Beta distribution 0–1 (mean ~0.5)
\(\text{bound}(\cdot, 0, 1)\) Clips the result to valid probability range [0, 1] —

Intuition for \(k\): When \(k = 0.25\), a one-standard-deviation shift in maturity (\(\Delta m = 0.2\)) changes the adoption probability by \(0.25 \times 0.2 = 0.05\) (5 percentage points).

Example: If hydrolysates have \(P_{\text{base}} = 0.75\) and \(k = 0.25\):

  • In a “bad world” (\(m = 0.2\)): \(P = 0.75 + 0.25 \times (0.2 - 0.5) = 0.675\)
  • In a “good world” (\(m = 0.8\)): \(P = 0.75 + 0.25 \times (0.8 - 0.5) = 0.825\)
What does “bound” mean?

bound(x, 0, 1) ensures the result stays between 0 and 1. Also called “clip” or “clamp” in programming.

  • If x < 0, return 0
  • If x > 1, return 1
  • Otherwise, return x

This prevents impossible probabilities like -0.2 or 1.3.

What Gets Correlated — And How It Maps to Equations

The maturity factor simultaneously adjusts multiple components. Here is how each connects to the equations above:

Component Effect when \(m\) is high Equation affected Justification
Technology adoption rates Higher \(P_{\text{adopted}}\) for hydrolysates, cheap GFs, food-grade \(P_{\text{adopted}} = \text{bound}(P_{\text{base}} + k(m-0.5), 0, 1)\) — Section 4 More R&D investment, proven pilots
Custom reactor share More facilities use food-grade equipment Affects CAPEX\(_{\text{ref}}\) via the custom reactor ratio — CAPEX section Supply chain development
WACC (financing cost) Lower \(r\) in the CRF formula \(\text{CRF} = \frac{r(1+r)^n}{(1+r)^n - 1}\) — Section 3 Reduced investor risk perception
Why should technology success correlate with cheaper financing?

This is not an assumption that technology causes cheaper financing. Rather, both are symptoms of the same underlying cause: industry development.

The causal story:

  1. If the cultured meat industry develops well by 2036, we’d expect:
    • More companies reaching commercial scale → proven unit economics
    • Successful pilots → reduced technology risk
    • Regulatory approvals → reduced market risk
    • Growing consumer acceptance → larger addressable market
  2. All of these reduce investor risk perception, which lowers WACC:
    • Early-stage ventures: 15–25% WACC (high risk premium)
    • Proven technology, growing market: 8–12% WACC (approaching food industry norms)
  3. The same favorable conditions that enable technology adoption also enable cheaper financing.

What the model is NOT saying:

  • ❌ “Cheap growth factors will magically make financing cheaper”
  • ✅ “Worlds where GF technology succeeds are also worlds where the industry is more developed, which independently leads to cheaper financing”

This is a latent variable approach: \(m\) represents unobserved industry development that affects multiple outcomes.

Why this matters: In a world where growth factor technology succeeds, it’s more plausible that: 1. Other technologies also succeed (shared R&D ecosystem) 2. Investors see lower risk (proven technology → cheaper capital) 3. Custom reactor suppliers exist (developed supply chain)

The maturity factor captures this “worlds come in bundles” intuition without requiring us to specify every pairwise correlation.

Limitation: This approach assumes all technologies develop together. In reality, some might succeed while others fail (e.g., cheap GFs but slow bioreactor scale-up). A more sophisticated model could specify different correlation structures, but this adds complexity without clear empirical grounding.

Could technologies develop independently? (Addressing correlation assumptions)

The objection: “Some forms of technical development might go together, and others less so. For example, growth factor breakthroughs might happen via biotech R&D that has nothing to do with bioreactor manufacturing.”

Valid scenarios this model doesn’t capture well:

Scenario What happens Model behavior
GF breakthrough, slow scale-up Precision fermentation works, but bioreactor suppliers don’t materialize Model assumes correlated — if GFs are cheap, custom reactors are likely
Scale-up success, expensive GFs Large bioreactors get built, but GF tech stalls Model assumes correlated — large scale implies cheap GFs
Regional divergence US gets cheap GFs, EU gets cheap reactors Model assumes global correlation

Why we use a single maturity factor anyway:

  1. Empirical correlation is plausible: Companies that solve GF problems often also have bioreactor expertise (vertical integration is common in this industry).

  2. Shared enabling conditions: Both GF tech and bioreactor scale-up benefit from investor confidence, regulatory clarity, and talent availability — all of which move together.

  3. Parsimony: Specifying a full correlation matrix (hydrolysates × GFs × reactors × WACC) would require ~10 pairwise correlations with no empirical data to calibrate them.

Sensitivity check: Users can explore partially-correlated scenarios by: - Setting maturity high but technology probabilities low (tests “scale-up succeeds, tech fails”) - Setting maturity low but one technology probability high (tests “isolated breakthrough”)

This manual exploration partially compensates for the model’s correlation structure.

5. Monte Carlo Simulation

The model runs 30,000 simulations, each time:

  1. Draw random values for all uncertain parameters
  2. Draw technology adoption outcomes (Bernoulli coin flips)
  3. Calculate unit cost for that scenario
  4. Collect results into a distribution

This produces the histograms and probability thresholds shown in the dashboard.

Parameter Definitions

This section defines all model inputs. Each parameter links back to where it appears in the cost equations.

Basic Parameters

Parameter Symbol Distribution Default Unit Used in
Plant capacity \(Q\) Lognormal(p5, p95) 5–50 kTA/year CAPEX/kg, Fixed OPEX
Utilization \(u\) Beta(mean, sd) 0.90 fraction Annual output = \(Q \times u\)
Maturity index \(m\) Beta(mean, sd) 0.50 0–1 Technology adoption, WACC adjustment

Why these distributions?

  • Lognormal for plant capacity: Capacity is positive and right-skewed (most plants are medium-sized, few are very large). Lognormal naturally captures this. The p5/p95 parameterization lets us specify “90% of plants are between 5 and 50 kTA.”
  • Beta for utilization and maturity: Both are bounded between 0 and 1. Beta distributions are flexible for modeling proportions and can be parameterized with mean/stdev.

These choices follow standard practice in techno-economic assessments (Humbird 2021, Risner et al. 2021). Humbird 2021 uses lognormal distributions for cost inputs and triangular distributions for some parameters; we use lognormal throughout for positive-valued quantities because it avoids the sharp bounds of triangular distributions. The Bernoulli draws for technology adoption (hydrolysates, food-grade, cheap GFs) reflect discrete yes/no events rather than continuous uncertainty — see Section 4 for details.

Technology Adoption

Each technology has a base adoption probability, adjusted by the maturity factor:

\[ P_{\text{adopted}} = \text{bound}(P_{\text{base}} + k \times (m - 0.5), 0, 1) \]

Technology Base Prob \(k\) Effect on cost Notes
Hydrolysates 75% 0.25 Reduces media $/L by ~70% Plant/yeast protein digests replace purified amino acids
Food-grade micronutrients 65% 0.20 Reduces micronutrient $/g by ~90% Food-grade vitamins, minerals, and trace elements vs. pharma-grade
Scalable GF technology 50% 0.25 Switches to “cheap” GF prices (see price tables) Any breakthrough: autocrine, plant farming, precision fermentation. See binary toggle rationale

Process Intensities

These parameters determine how much media is needed per kg of meat. They feed directly into the Media Cost equation:

\[\text{Media Cost} = \frac{1000}{\text{cell density}} \times \text{turnover} \times \text{price per L}\]

Parameter Range (p5–p95) Unit Definition Where in cost equation
Cell density 30–200 g/L Final biomass concentration at harvest Denominator of \(\frac{1000}{\text{density}}\) — higher density → fewer liters per kg
Cycle time 0.5–5 days Duration of one production batch Affects annual throughput (and thus CAPEX/kg via $/kg = CAPEX × CRF / output), not media cost directly
Media turnover 1–10 × Times media is replaced per batch Multiplier on liters/kg — perfusion (>1) uses more media but enables higher density

Media turnover explained: In batch mode (turnover = 1), the reactor is filled once and cells grow until nutrients deplete. In perfusion mode (turnover > 1), fresh media continuously flows in while spent media exits. Perfusion uses more media but achieves higher cell densities.

Micronutrient Costs

Micronutrients (vitamins, minerals, trace elements) are a smaller but still meaningful cost component. The technology switch P(food-grade) determines which price regime applies.

Grade Usage (g/kg meat) Price (\(/g) | Cost range (\)/kg) Source
Pharma-grade 1.0 – 10.0 $0.50 – $20 $0.50 – $200 Sigma-Aldrich catalog pricing
Food-grade 0.1 – 2.0 $0.02 – $2 $0.002 – $4 Commodity vitamin suppliers

Why the 90% cost reduction? Pharma-grade micronutrients require: - Ultra-high purity (>99.9%) with certificates of analysis - Controlled manufacturing environments (GMP) - Extensive documentation and traceability

Food-grade uses the same compounds at lower purity standards acceptable for human consumption, often sourced from feed or supplement supply chains.

Growth Factor Price Scenarios

These parameters feed into the GF Cost equation: GF Cost = \(g_{\text{GF}}\) (quantity) × \(P_{\text{GF}}\) (price).

The model uses two discrete price scenarios, selected by a Bernoulli draw (see why binary above):

Scenario Quantity (g/kg) Price ($/g) What it represents Source
Scalable tech achieved 0.0001 – 0.005 $1 – $100 At least one breakthrough reaches commercial scale GFI 2024 targets
Limited progress 0.0005 – 0.02 $500 – $50,000 Incremental improvements only; no step-change Current research prices

Why different quantities too? Breakthrough technologies often reduce both price and required amount:

  • Thermostable variants (e.g., FGF2-G3 from Enantis) have 20-day half-life vs. hours, reducing dosing frequency
  • Autocrine lines produce GFs continuously, maintaining optimal concentrations
  • Recycling systems recover GFs from spent media

Breakthrough technologies (any one could trigger “cheap”):

Technology Mechanism Current status Target price
Autocrine cell lines Cells engineered to produce own FGF2 Proof of concept ~$0/g
Plant molecular farming GFs expressed in tobacco, rice Pilot scale $1–10/g
Precision fermentation Microbial production at scale Scaling up $10–100/g
Small molecule substitutes Chemicals that activate GF receptors Research <$1/g

Capital Cost Parameters

This section explains how capital costs (bioreactors, facilities) are calculated. The key equation is:

\[\text{CAPEX}_{/\text{kg}} = \frac{\text{Total CAPEX} \times \text{CRF}}{\text{Annual Output}}\]

Where Total CAPEX depends on plant size and equipment type, and CRF converts a lump sum to annual payments (see Section 3 for the CRF formula).

Reference Scale: Why 20 kTA?

kTA = kilo-tonnes per annum (thousands of metric tons per year). So 20 kTA = 20,000 tonnes/year of cultured meat output. For context, a single large conventional chicken processing plant handles ~200 kTA, so 20 kTA is a modest commercial facility.

The model defines CAPEX at a reference scale of 20 kTA, then adjusts for actual plant size using economies of scale. We use 20 kTA because:

  1. It matches the scale in Risner et al. (2021), enabling direct comparison
  2. It represents a plausible first commercial-scale facility (current pilots are <1 kTA)
  3. Published cost estimates are most reliable around this scale — extrapolating far beyond it introduces large uncertainty

How the reference scale is used: We define “CAPEX at 20 kTA” as our baseline, then scale up or down using the economies of scale formula below. This is standard practice in chemical engineering cost estimation (“factored estimation” or “Lang factor” method).

Why pharma-grade appears here: The baseline CAPEX parameter ($5-25/kg capacity) is anchored to published estimates that assume pharmaceutical-grade equipment (316L stainless steel, full cleaning validation). Most TEAs use pharma-grade as the starting point because that is what current facilities use. The model then applies a custom reactor ratio (0.35-0.85) to simulate the cost reduction if food-grade equipment is adopted instead — so pharma-grade is the pessimistic baseline, not an assumption about the future.

Economies of Scale: The \(K \sim Q^s\) Relationship

Capital costs don’t scale linearly with capacity. A plant 10× larger doesn’t cost 10× more — it benefits from economies of scale:

\[\text{CAPEX} = \text{CAPEX}_{\text{ref}} \times \left(\frac{Q}{Q_{\text{ref}}}\right)^s\]

Where:

  • \(K\) = total capital cost (we use \(K\) as shorthand for CAPEX)
  • \(Q\) = plant capacity; \(Q_{\text{ref}}\) = reference capacity (20 kTA)
  • \(s\) = scale exponent (0.6–0.9)

What the exponent means:

Scale exponent \(s\) If capacity doubles… Example industries
1.0 CAPEX doubles (no economies) Modular, containerized systems
0.7 CAPEX increases 62% Chemical plants, refineries
0.6 CAPEX increases 52% Power plants, large bioreactors

The range 0.6–0.9 reflects uncertainty about whether cultured meat will achieve chemical-industry economies (0.6) or remain more modular (0.9).

Pharma-Grade vs. Food-Grade Equipment

Why this matters for CAPEX: The cultured meat industry emerged from pharmaceutical cell culture, which uses expensive equipment designed for injectable drugs. A key cost question is whether the industry can transition to simpler, cheaper food-grade equipment.

This distinction directly affects CAPEX\(_{\text{ref}}\) in the scaling equation — pharma-grade equipment costs 2–10× more than food-grade, and the custom reactor ratio parameter captures this uncertainty.

Pharma-grade bioreactors are built to pharmaceutical manufacturing standards:

  • 316L stainless steel, electropolished surfaces
  • Extensive validation, documentation (GMP compliance)
  • Designed for injectable drug production
  • Cost: $50–500 per liter installed capacity — typical pharmaceutical bioreactors cost £250,000+ for standard units

Food-grade (or “custom”) equipment is simpler:

The custom reactor ratio (0.35–0.85) represents the cost of food-grade equipment relative to pharma-grade. At 0.5, custom equipment costs half as much.

Parameter Range Definition Equation
WACC 8–20% Weighted average cost of capital \(r\) in CRF = \(\frac{r(1+r)^n}{(1+r)^n-1}\) — see Section 3
Asset life 8–20 years Equipment depreciation period for bioreactors, buildings, and support facilities \(n\) in CRF = \(\frac{r(1+r)^n}{(1+r)^n-1}\) — see Section 3
Scale exponent 0.6–0.9 Economies of scale power (how much CAPEX grows as plant capacity increases) \(s\) in \(\text{CAPEX} = \text{CAPEX}_{\text{ref}} \times (Q/Q_{\text{ref}})^s\) — see economies of scale section. Note: \(s\) (scale exponent) is distinct from \(r\) (WACC) used in the CRF formula.
Pharma-grade CAPEX \(5–25/kg capacity | Base capital cost at 20 kTA | CAPEX\)_{}$ in scaling equation
Custom reactor ratio 0.35–0.85 Food-grade ÷ pharma-grade cost Multiplier on CAPEX\(_{\text{ref}}\) when using food-grade

WACC Justification

WACC (Weighted Average Cost of Capital) represents the blended cost of debt and equity financing. Our 8–20% range reflects:

Benchmark Typical WACC Source
Established food companies (Tyson, JBS) 6–10% Industry averages (Damodaran)
Biotech startups (pre-revenue) 15–25% VC expected returns
Cultured meat companies 12–20% Humbird (2021), CE Delft (2021)

Why the range is wide: The low end (8%) assumes the industry matures to food-company norms – stable revenue, proven unit economics, low technology risk. The high end (20%) reflects today’s reality: most cultured meat companies are venture-backed with no revenue, unproven at scale, and facing regulatory uncertainty. As the industry matures (higher \(m\)), WACC should decline toward food-industry norms. Our 8-20% range brackets both Humbird’s 10% baseline and CE Delft’s 7-12% range.

Code Reference

The full model implementation is available in multiple formats:

Format Location Notes
JavaScript (interactive) Embedded in dashboard Primary implementation
Python (reference) dashboard/model.py Standalone script
Squiggle (reference) models/cm_cost_v0.2.squiggle Synced with dashboard parameters

Key Functions

The JavaScript implementation includes:

  • simulate(n, seed, params) — Main Monte Carlo loop
  • sampleLognormalP5P95(rng, p5, p95, n) — Sample from lognormal given percentiles
  • sampleBetaMeanStdev(rng, mean, sd, n) — Sample from beta distribution
  • crf(wacc, years) — Capital Recovery Factor calculation
  • spearmanCorr(x, y) — Rank correlation for sensitivity analysis

View the page source for the complete implementation.

Limitations

Known Limitations

  1. Static snapshot model — Projects costs for a single projection year (adjustable 2026-2050). Does not model year-over-year learning curves; instead, the “maturity” parameter serves as a proxy for cumulative industry development.

  2. Downstream is optional — Scaffolding, texturization, and forming costs can be included via toggle (+$2-15/kg for structured products).

  3. No geography — Assumes generic global costs, not region-specific labor, energy, or regulatory factors.

  4. Limited contamination modeling — No batch failure or contamination event distributions.

  5. Some correlations may be underspecified — While the maturity factor induces correlation between technology adoption, reactor costs, and WACC, other potential correlations (e.g., between cell density and cycle time) are treated as independent.

Recommendations for Use

Recommendation What it means Why
Use for relative comparisons Compare scenarios (e.g., “Cheap GF tech reduces costs by 40%”) rather than absolute predictions (“Costs will be $8.50/kg”) When parameters are uncertain, the difference between scenarios is more stable than the absolute baseline — see example below
Focus on probability thresholds Ask “What’s P(cost < $10/kg)?” not “What’s the expected cost?” Probabilities integrate over uncertainty and map to decisions (“Is this worth pursuing?”)
Validate parameters with experts Before publishing, check that ranges match current industry knowledge Published literature lags industry by 1–3 years; some parameters (GF costs) change rapidly
Report uncertainty ranges Always show 90% CI, not just median Wide intervals reflect genuine uncertainty; suppressing them gives false confidence
Explore correlated scenarios Use the maturity slider to see “good world” vs “bad world” bundles Technologies, financing, and supply chains often develop together — though some breakthroughs (e.g., GF biotech) may be partially independent of others (e.g., bioreactor manufacturing). See correlation assumptions for discussion

What “relative comparisons” means in practice

✅ Good use: “Achieving 150 g/L cell density instead of 50 g/L would reduce costs by 40–60%”

❌ Risky use: “Cultured chicken will cost $8.50/kg by 2030”

The model is better at estimating how much a technology improvement helps than what the final cost will be, because relative effects are less sensitive to baseline assumptions.

Sources

Changelog

Version Date Changes
v0.3 2026-02 Separated Learn page, consolidated technical docs
v0.2 2026-02 Explicit scale/uptime, beta distributions, maturity factor
v0.1 2026-01 Initial Squiggle model based on UC Davis